LSL Pharma Group Inc. (TSXV: LSL)
Canada
· Delayed Price · Currency is CAD 0.350
0.00 (0.00%)
Dec 20, 2024, 1:19 PM EST
LSL Pharma Group Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 29, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 30, 2022 | Dec '21 Dec 30, 2021 | Dec '20 Dec 30, 2020 | Oct '20 Oct 2, 2020 |
| Revenue | 15.82 | 10.03 | 8.21 | 8.77 | 10.05 | 4.82 |
| Revenue Growth (YoY) | 78.60% | 22.08% | -6.35% | -12.70% | 108.32% | - |
| Cost of Revenue | 11.85 | 8.38 | 10.39 | 6.89 | 6.85 | 4.66 |
| Gross Profit | 3.98 | 1.65 | -2.17 | 1.88 | 3.2 | 0.16 |
| Selling, General & Admin | 4.13 | 3.57 | 3.92 | 2.59 | 1.52 | -0.3 |
| Research & Development | 0.07 | 0.07 | 0.67 | - | - | - |
| Operating Expenses | 4.6 | 5.76 | 4.59 | 2.59 | 1.52 | -0.3 |
| Operating Income | -0.63 | -4.12 | -6.76 | -0.71 | 1.68 | 0.46 |
| Interest Expense | -1.84 | -1.76 | -1.39 | -1.71 | -1.26 | -0.53 |
| Other Non Operating Income (Expenses) | -0.05 | -0.05 | -0.15 | - | -0.17 | -0.19 |
| EBT Excluding Unusual Items | -2.52 | -5.92 | -8.29 | -2.41 | 0.25 | -0.27 |
| Merger & Restructuring Charges | -2.57 | -2.55 | -0.43 | - | - | - |
| Other Unusual Items | 2.63 | - | 0.66 | 0.78 | 0.57 | 0.35 |
| Pretax Income | -2.45 | -8.47 | -8.06 | -1.63 | 0.82 | 0.08 |
| Income Tax Expense | - | - | - | 0.15 | 0.21 | -0.01 |
| Net Income | -2.45 | -8.47 | -8.06 | -1.78 | 0.61 | 0.09 |
| Net Income to Common | -2.45 | -8.47 | -8.06 | -1.78 | 0.61 | 0.09 |
| Net Income Growth | - | - | - | - | 592.98% | - |
| Shares Outstanding (Basic) | 97 | 80 | 66 | 59 | 55 | 48 |
| Shares Outstanding (Diluted) | 97 | 80 | 66 | 59 | 55 | 48 |
| Shares Change (YoY) | 24.72% | 20.88% | 11.78% | 8.34% | 14.88% | - |
| EPS (Basic) | -0.03 | -0.11 | -0.12 | -0.03 | 0.01 | 0.00 |
| EPS (Diluted) | -0.03 | -0.11 | -0.12 | -0.03 | 0.01 | 0.00 |
| EPS Growth | - | - | - | - | 503.48% | - |
| Free Cash Flow | -4.88 | -7.73 | -4.16 | -2 | -4.47 | -0.2 |
| Free Cash Flow Per Share | -0.05 | -0.10 | -0.06 | -0.03 | -0.08 | -0.00 |
| Gross Margin | 25.13% | 16.40% | -26.44% | 21.47% | 31.83% | 3.29% |
| Operating Margin | -3.96% | -41.05% | -82.26% | -8.07% | 16.74% | 9.54% |
| Profit Margin | -15.50% | -84.48% | -98.15% | -20.26% | 6.07% | 1.82% |
| Free Cash Flow Margin | -30.85% | -77.04% | -50.66% | -22.80% | -44.47% | -4.22% |
| EBITDA | 0.43 | -3.21 | -5.97 | 0.1 | 2.51 | 0.76 |
| EBITDA Margin | 2.70% | -32.03% | -72.67% | 1.17% | 25.01% | 15.71% |
| D&A For EBITDA | 1.05 | 0.9 | 0.79 | 0.81 | 0.83 | 0.3 |
| EBIT | -0.63 | -4.12 | -6.76 | -0.71 | 1.68 | 0.46 |
| EBIT Margin | -3.96% | -41.05% | -82.26% | -8.07% | 16.74% | 9.54% |
| Effective Tax Rate | - | - | - | - | 25.92% | - |
Source: S&P Capital IQ. Standard template. Financial Sources.